Results 161 to 170 of about 17,380 (208)
Some of the next articles are maybe not open access.
A case of thrombotic microangiopathy/microangiopathies
Blood Coagulation & Fibrinolysis, 2014We report a case of Streptococcus pneumonia sepsis-associated disseminated intravascular coagulation (DIC) with features of acute renal failure and microvascular thrombosis characterized by skin purpura and bilateral foot necrosis. The persistence of laboratory features of microangiopathic hemolytic anemia despite aggressive correction of DIC ...
Zhineng J, Yang +2 more
openaire +2 more sources
Emergency Medicine Clinics of North America
Thrombotic microangiopathies (TMAs) are rare diseases characterized by endothelial injury and microvascular clots. TMAs often lead to microangiopathic hemolytic anemia, thrombocytopenia, and end organ damage. Common TMA types include thrombotic thrombocytopenic purpura (TTP), infection-associated hemolytic uremic syndrome, and complement-mediated TMAs.
Ramy, Hanna +2 more
openaire +2 more sources
Thrombotic microangiopathies (TMAs) are rare diseases characterized by endothelial injury and microvascular clots. TMAs often lead to microangiopathic hemolytic anemia, thrombocytopenia, and end organ damage. Common TMA types include thrombotic thrombocytopenic purpura (TTP), infection-associated hemolytic uremic syndrome, and complement-mediated TMAs.
Ramy, Hanna +2 more
openaire +2 more sources
Seminars in Arthritis and Rheumatism, 2014
To review the clinical features and pathophysiologic mechanisms of the thrombotic microangiopathies (TMAs) including acquired and congenital thrombotic thrombocytopenic purpura (TTP), Shiga toxin-induced and atypical (non-Shiga toxin-induced) hemolytic uremic syndrome (HUS), and the TMAs associated with pregnancy, drugs, and organ transplantation ...
openaire +2 more sources
To review the clinical features and pathophysiologic mechanisms of the thrombotic microangiopathies (TMAs) including acquired and congenital thrombotic thrombocytopenic purpura (TTP), Shiga toxin-induced and atypical (non-Shiga toxin-induced) hemolytic uremic syndrome (HUS), and the TMAs associated with pregnancy, drugs, and organ transplantation ...
openaire +2 more sources
Thrombotic microangiopathy in pregnancy
Thrombosis Research, 2009Following the initial reports by Moschowitz in 1925 [1] and by Baehr et al. in 1936 [2], Singer [3] and Gasser [4] suggested the terms of “thrombotic thrombocytopenic purpura, TTP” and of “hemolytic uremic syndrome, HUS” to describe related disorders consisting of Coombs’ negative hemolytic anemia, thrombocytopenia, and renal failure.
Armando, D'Angelo +2 more
openaire +2 more sources
Syndromes of Thrombotic Microangiopathy
Medical Clinics of North America, 2017Thrombotic thrombocytopenia purpura (TTP) and the hemolytic uremic syndrome (HUS) are rare thrombotic microangiopathies that can be rapidly fatal. Although the acquired versions of TTP and HUS are generally highest on this broad differential, multiple rarer entities can produce a clinical picture similar to TTP/HUS, including microangiopathic hemolysis,
Joseph J, Shatzel, Jason A, Taylor
openaire +2 more sources
Thrombotic Microangiopathy in Cancer
Seminars in Thrombosis and Hemostasis, 2018AbstractThrombotic microangiopathy (TMA) is a rare but often devastating complication of cancer and cancer treatment. The syndrome is defined by thrombocytopenia (i.e., a platelet count of < 150,000/mcL or > 30% decrease from baseline), microangiopathic hemolytic anemia, and some evidence of organ damage.
openaire +3 more sources
Thrombotic Microangiopathy in the Cancer Patient
Acta Haematologica, 2001Thrombotic microangiopathy, manifesting as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome, is a common complication in cancer patients. It shares the pathogenic microvascular occlusive lesion and many clinical manifestations as the classical TTP, but the spectrum of complications varies widely.
H C, Kwaan, L I, Gordon
openaire +2 more sources
Gemcitabine‐induced thrombotic microangiopathy
Internal Medicine Journal, 2013AbstractThrombotic microangiopathy (TMA) is a microvascular occlusive disorder characterised by platelet aggregation, thrombocytopenia and end‐organ damage. It is commonly idiopathic, although several drug classes, including cytotoxic chemotherapy, have been implicated.
Richmond, J., Gilbar, P., Abro, E.
openaire +5 more sources
2019
Abstract The thrombotic microangioapathy (TMA) syndromes are characterized by concomitant occurrence of severe thrombocytopenia, microangiopathic hemolytic anemia, and ischemic end organ dysfunction often of the kidneys. While several of their features overlap in terms of clinical presentation, the pathophysiology and underlying causes ...
Harpreet Singh +2 more
+4 more sources
Abstract The thrombotic microangioapathy (TMA) syndromes are characterized by concomitant occurrence of severe thrombocytopenia, microangiopathic hemolytic anemia, and ischemic end organ dysfunction often of the kidneys. While several of their features overlap in terms of clinical presentation, the pathophysiology and underlying causes ...
Harpreet Singh +2 more
+4 more sources
Thrombotic Microangiopathies and the Kidney
Advances in Kidney Disease and HealthThrombotic microangiopathy (TMA) is a pathological lesion that occurs due to endothelial injury. It can be seen in a heterogenous group of disorders, typically characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end-organ ischemia. TMA can also be renal limited with no systemic manifestations.
Anuja Java +2 more
openaire +2 more sources